文献速递类风湿关节炎

类风湿关节炎患者经阿达木单抗联合甲氨蝶呤达到低疾病活动度后长期使用阿达木单抗单药治疗

Long-term use of adalimumab as monotherapy after attainment of low disease activity with adalimumab plus methotrexate in patients with rheumatoid arthritis.
PubMed 文献 · RMD Open · 2018-06-13

本研究为开放标签延伸研究的post hoc分析,纳入经阿达木单抗联合甲氨蝶呤治疗2年达到低疾病活动度(DAS28(CRP)<3.2)的早期类风湿关节炎患者,评估后续阿达木单抗单药治疗或重新启用甲氨蝶呤的长期结局。结果显示,阿达木单抗单药治疗可在额外3年内有效维持良好的临床、功能和影像学结局,≥50%的患者达标,且不用甲氨蝶呤与使用甲氨蝶呤的患者不良事件发生率相似。

要点

  • 阿达木单抗单药治疗可在额外3年内维持≥50%患者的良好临床、功能和影像学结局。
  • 不用甲氨蝶呤与使用甲氨蝶呤的患者不良事件发生率相似。
  • 不用甲氨蝶呤患者第5年低疾病活动度维持率63%,使用甲氨蝶呤患者为61%。

核心结论

  • 对于经阿达木单抗联合甲氨蝶呤治疗2年达到低疾病活动度的患者,阿达木单抗单药治疗可在额外3年内有效维持良好的临床、功能和影像学结局,≥50%的患者达标。

研究设计与样本

  • 本研究为开放标签延伸研究的post hoc分析,纳入在双盲2年研究中经阿达木单抗联合甲氨蝶呤治疗达到低疾病活动度(DAS28(CRP)<3.2)的早期类风湿关节炎患者,评估后续阿达木单抗单药治疗或重新启用甲氨蝶呤的结局,数据截至开放标签延伸研究第3年(研究第5年)。

主要发现

  • 在140例启动阿达木单抗单药治疗的患者中,84例(60%)仅使用阿达木单抗(不用甲氨蝶呤),56例(40%)重新启用甲氨蝶呤(使用甲氨蝶呤)。
  • 首次使用甲氨蝶呤的中位时间(IQR)为5.1(0.1-31.4)周。
  • 第5年时,使用甲氨蝶呤患者中61%维持低疾病活动度、48%达到DAS28(CRP)<2.6、45%物理功能正常、46%无影像学进展。
  • 第5年时,不用甲氨蝶呤患者中63%维持低疾病活动度、50%达到DAS28(CRP)<2.6、58%物理功能正常、50%无影像学进展。
  • 不用甲氨蝶呤与使用甲氨蝶呤患者的不良事件发生率相似。

关键数值与推荐

  • 低疾病活动度定义为DAS28(CRP)<3.2。
  • 物理功能正常定义为健康评估问卷残疾指数<0.5。
  • 影像学无进展定义为改良总Sharp评分变化≤0.5。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate long-term clinical, functional and radiographic outcomes in an open-label extension (OLE) study in patients with rheumatoid arthritis (RA) receiving adalimumab monotherapy or adalimumab+methotrexate following attainment of low disease activity (LDA) with adalimumab+methotrexate. METHODS: Methotrexate-naive patients with early RA were randomised to adalimumab, methotrexate or adalimumab +methotrexate in a double-blind, 2-year study. Patients who completed the study and achieved LDA (28-joint Disease Activity Score using C reactive protein (DAS28(CRP)<3.2) could receive adalimumab monotherapy for up to 8 additional years in the OLE; open-label methotrexate could be added per investigator's discretion. This post hoc analysis included data up to OLE year 3 (study year 5) from patients receiving adalimumab+methotrexate who achieved LDA at year 2 followed by adalimumab monotherapy or methotrexate reinitiation. Normal physical function was defined as Disability Index of the Health Assessment Questionnaire <0.5 and radiographic non-progression as change in modified total Sharp score ≤0.5. RESULTS: Of 140 patients initiating adalimumab monotherapy, 84 (60%) received adalimumab only (methotrexate non-use) and 56 (40%) reinitiated methotrexate (methotrexate use) during OLE treatment. Median (IQR) time to first methotrexate use was 5.1 (0.1-31.4) weeks. Among methotrexate users, 61% retained LDA, 48% achieved DAS28(CRP) <2.6, 45% had normal physical function and 46% had no radiographic progression at year 5; for non-users, 63%, 50%, 58% and 50%, respectively, achieved these milestones. Adverse event rates were similar between methotrexate non-use and use patients. CONCLUSIONS: Adalimumab monotherapy effectively maintained good clinical, functional and radiographic outcomes for up to 3 additional years in ≥50% of patients who attained LDA after 2 years of adalimumab+methotrexate therapy. TRIAL REGISTRATION NUMBER: NCT00195663; Post-results.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Keystone EC, Breedveld FC, Kupper H, et al. Long-term use of adalimumab as monotherapy after attainment of low disease activity with adalimumab plus methotrexate in patients with rheumatoid arthritis. RMD Open. 2018. PMID: 29955381. doi:10.1136/rmdopen-2017-000637

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。